Daniel A. Grabell

Daniel A. Grabell

Auto-generated profile, based on publicly available information

Daniel A. Grabell

Department of Dermatology, University of Texas Health Science Center at Houston, Houston, USA

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 August 2014 in Arthritis & Rheumatology
Verified
Journal Article
Open access
PDF file
DCDaniel Condie
Daniel Condie
DGDaniel Grabell
Daniel Grabell
HJHeidi Jacobe
Heidi Jacobe
Objective: Few studies have examined outcomes in adults with pediatric‐onset morphea. The objective of the present study was to compare clinical outcomes and health‐related quality of life (HRQOL) in adults with onset of morphea in childhood to those in patients with adult onset of morphea.Methods: Participants in the study were drawn from the Morphea in Adults and Children cohort and included 68 adults with pediatric‐onset morphea and 234 patients with adult‐onset morphea. Outcome measures included the Localized Scleroderma Cutaneous Assessment Tool (LoSCAT), physical examination findings, and HRQOL questionnaires.Results: Adults with pediatric‐onset morphea were younger, had longer disease duration, and were more likely to have the linear subtype of morphea. Patients with pediatric‐onset disease were less likely to have active disease. Among patients with active disease, those with pediatric‐onset morphea had less disease activity as measured by the LoSCAT. Patients with pediatric‐onset disease had higher severity of disease damage when measured by the physician's global assessment of damage, but had similar levels of disease damage when measured by the Localized Scleroderma Skin Damage Index. Patients with pediatric‐onset disease had more favorable HRQOL scores for all measures, all of which were statistically significantly different from those in patients with adult‐onset morphea.Conclusion: Adults with pediatric‐onset morphea differ from patients with adult‐onset disease with respect to disease subtype, severity of disease activity and damage, and levels of HRQOL.

1 September 2014 in Journal of the American Academy of Dermatology
Verified
Journal Article
Closed access
DGDaniel Grabell
Daniel Grabell
CHClifford Hsieh
Clifford Hsieh
RARachel Andrew
Rachel Andrew
KMKathryn Martires
Kathryn Martires
AKAndrew Kim
Andrew Kim
HJHeidi Jacobe
Heidi Jacobe

27 October 2016 in Dermatology and Therapy
Verified
Journal Article
Open access
PDF file
DGDaniel A. Grabell
Daniel A. Grabell
AHAdelaide A. Hebert
Adelaide A. Hebert
Hyperhidrosis is defined as the production of sweat beyond what is physiologically necessary to maintain thermal homeostasis. This disease state may (and typically does) have a significant impact on the patient’s quality of life. Medications including antiperspirants, anticholinergics, and botulinum toxin have been shown to be effective in the management of hyperhidrosis. Several medical device technologies have also proven to be effective. This review article will explore the current and emerging pharmacological and medical device treatments for hyperhidrosis and provide a framework for treating patients who suffer with primary forms of hyperhidrosis.

16 June 2022 in Journal of General Internal Medicine
Verified
Journal Article
Closed access
PDF file
ABAshley E. Brown
Ashley E. Brown
MNMaleka Najmi
Maleka Najmi
TDTaylor Duke
Taylor Duke
DGDaniel A. Grabell
Daniel A. Grabell
MKMisha V. Koshelev
Misha V. Koshelev
KNKelly C. Nelson
Kelly C. Nelson

1 May 2015 in JAMA Dermatology
Verified
Journal Article
Open access
PDF file
DGDaniel A. Grabell
Daniel A. Grabell
LMLoderick A. Matthews
Loderick A. Matthews
KYKim B. Yancey
Kim B. Yancey
BCBenjamin F. Chong
Benjamin F. Chong
Importance Anti–type VII collagen autoantibodies are often detectable in patients with bullous systemic lupus erythematosus (BSLE). However, the timing of their appearance preceding the onset of disease is unknown to date. Observations We report the case of a 50-year-old woman with a history of SLE who was seen with vesicles and bullae around her lips, trunk, axillae, arms, and thighs. Histologic analysis and immunofluorescence and immunoblot studies confirmed the diagnosis of BSLE. Immunoblotting and enzyme-linked immunosorbent assay studies of the patient’s serum obtained 3 months before the onset of BSLE showed the presence of anti–type VII collagen autoantibodies. Levels of anti–type VII collagen IgG increased after bullous lesions appeared. Within 1 month after initiating dapsone therapy and increasing the dosage of prednisone, skin lesions promptly resolved. One year after the onset of BSLE, the anti–type VII collagen IgG decreased below levels observed before the inception of the bullous lesions. Conclusions and Relevance Anti–type VII collagen autoantibodies can precede the clinical appearance of BSLE. The subsequent increase and decrease in levels of circulating anti–type VII collagen autoantibodies, which mirrored skin disease activity, support a potential role in their initiation of disease.

15 April 2013 in Cancer Research
Verified
Journal Article
Closed access
DGDaniel A. Grabell
Daniel A. Grabell
YWYu Wen
Yu Wen
NSNeha Semlani
Neha Semlani
JLJiadong Li
Jiadong Li
JGJames Goydos
James Goydos
Previously our group reported the identification of metabotropic glutamate receptor (GRM1) as an oncogene and as a potential therapeutic target of melanoma. We reported two clinical trials of Riluzole, an FDA approved glutamate release inhibitor for ALS, in advanced melanoma patients that showed suppression of PI3K/AKT and MAPK pathway and demonstrated clinical response of 34%. Recently, our lab found that over expression of GRM1 in a low GRM1-expressing melanoma cell line UACC903 GRM1+, BRAFV600E, PTENMUT, stimulates angiogenesis through activating the signaling pathway of AKT-mTOR-HIF1-IL8, VEGF even under the normoxia condition. We also demonstrated that Riluzole inhibits angiogenesis through the signaling pathway of GRM1/AKT/HIF1 among the patients responding to Riluzole in our phase II clinical trial. To facilitate translating the discovery of GRM1 stimulating angiogenesis into clinic, we designed an in vitro pre-clinical study assessing the combinatory effects of Riluzole with the agents targeting the angiogenesis pathway of GRM1.